A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The FDA has approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around four in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.